# Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting

> **NCT07132086** · — · COMPLETED · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 31 (actual)

## Conditions studied

- Insomnia Chronic

## Interventions

- **DRUG:** Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting

## Key facts

- **NCT ID:** NCT07132086
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-06-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132086, "Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07132086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*